Hey readers! Here's an idea that runs against decades of textbook framing: the immune cells at the heart of celiac disease may be too weak, not too fired up. This week we dig into that finding, pair it with a gluten-threshold study you can actually read the chart on, a drug deal worth watching, and some real-world wins (yes, gluten-free Goldfish are coming). Let's get into it.
🧬 Rethinking the immune story
Celiac Disease May Begin With Weak Immune Cells, Not an Overactive Response
Researchers at WEHI in Melbourne report in Immunology & Cell Biology that CD4 helper T cells from people with celiac disease looked weaker than those from healthy volunteers: they made less interleukin-2, divided more slowly after activation, and died off sooner.
- Udumbara Magazine, reporting on WEHI
What makes this interesting for clinicians and patients alike is that the pattern held across the board, regardless of sex, whether people were newly diagnosed, or whether they'd been gluten-free for years. That consistency is the tell.
"This tells us the effect isn't simply driven by inflammation or diet," said Dr. Vanessa Bryant. "It suggests an underlying difference that may be linked to genetic risk."
Bryant described the team's method with a memorable image:
"Our assay is a bit like winding up a toy and letting it go to see how long it runs and what tricks it performs."
To be clear, this is not a test you can ask for at your next appointment. The authors say larger, long-term studies are needed before any of it reaches the clinic. But the direction of travel, toward earlier risk identification rather than just reacting after symptoms, is worth watching.
Machine learning reveals HLA-DQ2.5's impact on naïve T-cell receptors
A second study, in Immunogenetics, offers a useful reality check on how hard "celiac-specific" immune signals are to isolate: a machine-learning model trained on naïve T-cell receptor data could sort patients from controls, but the signal it was really reading was the inherited risk gene HLA-DQ2.5.
- scienmag
The numbers tell the story. In the main Norwegian cohort (103 celiac patients, 103 controls), disease classification was moderate at around AUROC 0.72, but predicting DQ2.5 status was strong (median AUROC 0.972). When the analysis was limited to only DQ2.5-positive people, the apparent celiac-detecting power collapsed to about 0.5, no better than a coin flip.
Instead, it was reading a powerful genetic risk factor that shapes the immune system before it has encountered gluten.
Read alongside the WEHI work, both papers point to the same theme: a lot of what looks like "celiac immune activity" may actually be inherited wiring present before gluten ever enters the picture. That's genuinely useful context if you're a family trying to understand why one relative develops the disease and another doesn't.
📊 How little gluten sets off the immune system
Should the Gluten Threshold Dose in Celiac Disease Change Based on Immune Activation?
A randomized, double-blind, placebo-controlled trial in 51 adults with biopsy-proven celiac disease measured how gluten challenges (1 to 1000 mg) drove acute interleukin-2 responses, and the chart above lays out the estimated eliciting doses.
- gutsandgrowth
Gluten produced dose-dependent IL2 spikes: at least a 2-fold rise in 83% of participants at both 1000 mg and 610 mg, dropping off at lower doses, with no responders at 5 mg and below or to placebo. The estimated eliciting doses landed at ED50 of 111 mg and ED05 of 0.8 mg.
Here's the nuance worth holding onto. The authors argue the daily threshold should be lowered because measurable immune activation showed up at 3 mg, below current gluten-free labeling limits. But the editorial pumps the brakes:
Because symptoms did not correlate with the result of the IL2 test for gluten doses <1 g, further prolonged microchallenge studies remain the only reliable strategy to investigate the correlation between the IL2 test and the gold standard of CeD activity.
In plain terms: an immune blip in a blood test is not the same as intestinal damage you'd feel. As the piece's author notes, the data show activation at low exposures but do not prove that changing the labeling threshold would actually help patients. File this under "important, unsettled."
💊 A drug deal worth watching
argenx Completes Acquisition of Forte Biosciences
On August 27, 2026, argenx closed its acquisition of Forte Biosciences, folding in FB102, an anti-CD122 antibody with early proof-of-concept in both vitiligo and celiac disease.
- MarketMinute
The deal was a cash tender at $77.00 per share. What matters for this audience is the pipeline: FB102 targets pathogenic T-cell and NK-cell activity, and positive celiac data was announced in June 2025, with Phase 2 celiac results expected in the second half of 2026.
"At argenx, we measure our progress through patient impact, and the Forte acquisition deepens that impact," said CEO Karen Massey.
Celiac has no approved drug therapy, so any late-stage candidate reaching Phase 2 readouts this year is worth keeping on your radar, even if it's still early.
🫁 A complication case to know
Rare Lung Condition Expands Celiac Disease's Known Complications
A case report in Respirology Case Reports describes a 55-year-old man with long-standing celiac disease who developed progressive lung fibrosis with a biopsy-proven usual interstitial pneumonia (UIP) pattern, eventually needing a double lung transplant.
- scienmag
The tissue left behind told a story respiratory medicine rarely encounters: a biopsy-proven pattern of usual interstitial pneumonia... in a patient whose only standing diagnosis was gluten-sensitive enteropathy.
After ruling out environmental exposures, connective tissue disease, telomeropathy, and other causes, the team raised celiac-associated pulmonary involvement as a leading consideration. This is a single case, not a trend, but it's a reminder for practitioners to think broadly when a celiac patient presents with unexplained systemic symptoms.
🤱 A postpartum finding for celiac moms
Impact of breastfeeding on serological recovery in postpartum women with celiac disease
A longitudinal study of 255 women in Central Spain, followed from the third trimester to 12 months postpartum, found that exclusive breastfeeding was associated with a higher rate of serological remission at 12 months (92%) than formula feeding (74%, p < 0.001).
- Frontiers in Global Women's Health
Breastfeeding was also independently linked to faster decline in tTG-IgA, better ferritin recovery, and improved bone Z-scores. The authors describe breastfeeding as a beneficial physiological modulator during the postpartum transition. As always, feeding decisions are personal and individual, but this is a helpful data point for new mothers managing celiac disease.
🛒 Living gluten-free: wins, warnings, and where to shop
A quick lightning round of the human side of this diagnosis this week:
Broccoli and Cauliflower Chips Sold on Amazon Are Recalled Over Gluten Not on the Label - Momchipz Veggie Chips (Broccoli Florets and Cauliflower) were recalled for undeclared gluten; the 3-ounce bags carry a best-before date of August 31, 2026 and, notably, no lot code to cross-reference. If you bought these in spring, check your pantry. - Medical Daily
West Linn girl with celiac disease gets a surprise from Goldfish - Brooklynn Meeker wrote to Pepperidge Farm asking them to make a gluten-free Goldfish, the company kept her letter, and Goldfish Gluten Free crackers are scheduled to hit shelves in November. A rare feel-good product update with a real launch date. - KPTV
Dylan Dreyer reveals the 'unfair' part of son Calvin's celiac diagnosis - The TODAY meteorologist described tossing scratched pots, wooden spoons, and cutting boards to fight cross-contamination, and praised UK chains like Waitrose for affordable gluten-free staples. - HELLO!
"All of my stuff in the kitchen had to be thrown out, all of our wooden spoons, wooden cutting boards, anything that had a scratch in it... All of that had to be thrown out because gluten can hide everywhere."
On Dreyer's point about how hard it is to find safe options: when you're traveling or scouting a new restaurant, Find Me Gluten Free is a genuinely useful site and app for spotting celiac-friendly spots and reading reviews from other gluten-free diners. We're not sponsored by them, it's just a tool a lot of readers lean on.
And one more diagnosis story worth a nod: actress Jennie Garth says she "just found out I'm celiac" after "suffering for years," a reminder of how long the road to diagnosis can be. - Yahoo/PEOPLE
That's the issue. Take care of your gut, double-check those pantry labels, and we'll see you next time.